Johnson and Johnson 2013 Annual Report Download - page 15

Download and view the complete annual report

Please find page 15 of the 2013 Johnson and Johnson annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 84

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74
  • 75
  • 76
  • 77
  • 78
  • 79
  • 80
  • 81
  • 82
  • 83
  • 84

Pharmaceutical Segment
The Pharmaceutical segment achieved sales of $28.1 billion in 2013, representing an increase of 10.9% over the prior
year, with strong operational growth of 12.0% and a negative currency impact of 1.1%. U.S. sales were $13.9 billion, an
increase of 12.3%. International sales were $14.2 billion, an increase of 9.6%, which included 11.8% operational growth
and a negative currency impact of 2.2%. The Pharmaceutical segment operational growth was impacted by 0.8% in 2013
due to a positive adjustment to previous estimates for Managed Medicaid rebates.
Major Pharmaceutical Therapeutic Area Sales:*
% Change
(Dollars in Millions) 2013 2012 2011 ’13 vs. ’12 ’12 vs. ’11
Total Immunology $9,190 7,874 6,798 16.7% 15.8
REMICADE®6,673 6,139 5,492 8.7 11.8
SIMPONI®932 607 410 53.5 48.0
STELARA®1,504 1,025 738 46.7 38.9
Other Immunology 81 103 158 (21.4) (34.8)
Total Infectious Diseases 3,550 3,194 3,189 11.1 0.2
INCIVO®517 443 82 16.7 **
INTELENCE®379 349 314 8.6 11.1
PREZISTA®1,673 1,414 1,211 18.3 16.8
Other Infectious Diseases 981 988 1,582 (0.7) (37.5)
Total Neuroscience 6,667 6,718 6,948 (0.8) (3.3)
CONCERTA®/methylphenidate 782 1,073 1,268 (27.1) (15.4)
INVEGA®583 550 499 6.0 10.2
INVEGA®SUSTENNA®/XEPLION®1,248 796 378 56.8 **
RISPERDAL®CONSTA®1,318 1,425 1,583 (7.5) (10.0)
Other Neuroscience 2,736 2,874 3,220 (4.8) (10.7)
Total Oncology 3,773 2,629 2,048 43.5 28.4
VELCADE®1,660 1,500 1,274 10.7 17.7
ZYTIGA®1,698 961 301 76.7 **
Other Oncology 415 168 473 ** (64.5)
Total Other 4,945 4,936 5,385 0.2 (8.3)
ACIPHEX®/PARIET®470 835 975 (43.7) (14.4)
PROCRIT®/EPREX®1,364 1,462 1,623 (6.7) (9.9)
XARELTO®864 239 25 ** **
Other 2,247 2,400 2,762 (6.4) (13.1)
Total Pharmaceutical Sales $28,125 25,351 24,368 10.9% 4.0
* Prior year amounts have been reclassified to conform to current year presentation.
** Percentage greater than 100%
Immunology products achieved sales of $9.2 billion in 2013, representing an increase of 16.7% as compared to the prior
year. The increased sales of STELARA®(ustekinumab), SIMPONI®(golimumab) and REMICADE®(infliximab) were
primarily due to market growth and market share gains.
Certain patents related to REMICADE®(infliximab) expired in Canada in March 2012. In certain countries in Europe the
patent has been extended to February 2015 (Germany, Spain, United Kingdom, Sweden, Austria, Belgium, Switzerland,
Denmark, France, Greece, Italy, Luxembourg and the Netherlands). Loss of exclusivity for REMICADE®in these markets
may result in a reduction in sales. The U.S. patents for REMICADE®expire in 2018.
Johnson & Johnson 2013 Annual Report •5